Aspire Biopharma Holdings, Inc.
ASBP · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | |
|---|---|---|---|
| Valuation | |||
| PEG Ratio | -0.01 | 36.81 | 0.00 |
| FCF Yield | -0.37% | -0.12% | -0.95% |
| EV / EBITDA | -47.19 | -1,475.47 | -885.58 |
| Quality | |||
| ROIC | 1,130.32% | 281.85% | -0.20% |
| Gross Margin | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.16 | -0.15 | 0.24 |
| Growth | |||
| Revenue 3-Year CAGR | – | -100.00% | -100.00% |
| Free Cash Flow Growth | -214.60% | 87.04% | 0.00% |
| Safety | |||
| Net Debt / EBITDA | -0.11 | -0.97 | 0.83 |
| Interest Coverage | -3.46 | -39.99 | 0.00 |
| Efficiency | |||
| Inventory Turnover | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 |